Browsing Centre for Neuroscience, Surgery and Trauma by Subject "multiple sclerosis"
Now showing items 1-20 of 39
-
Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
(2020-06-12)While the major phenotypes of multiple sclerosis (MS) and relapsing-remitting, primary and secondary progressive MS have been well characterized, a subgroup of patients with an active, aggressive disease course and rapid ... -
Aggressive multiple sclerosis (2): Treatment.
(2020-06-12)The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at ... -
Alemtuzumab depletion failure can occur in multiple sclerosis.
(2018-06)Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ... -
Association between pathological and MRI findings in multiple sclerosis.
(Elsevier/Science Direct, 2012-03-19)Pathological evaluation is the gold standard for identifying processes related to multiple sclerosis that explain disease manifestations, and for guiding the development of new treatments. However, there are limitations ... -
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
(2018-11)BACKGROUND:: Reversible lymphocyte count reductions have occurred following daclizumab beta treatment for relapsing-remitting multiple sclerosis. OBJECTIVE:: To analyse total and differential lymphocyte levels and relationship ... -
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
(2018-04)Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ... -
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
(2023)BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges ... -
e-Health and multiple sclerosis: An update.
(2018-11)e-Health (or digital healthcare) is becoming increasingly relevant in multiple sclerosis (MS) clinical management. We aim to review and discuss current status and future perspective of e-health in people with multiple ... -
Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
(Sage Publications, 2018-04-21)BACKGROUND: It was recently reported that, using Western blotting, some multiple sclerosis (MS) patients in the United States had antibodies against epsilon toxin (Etx) from Clostridium perfringens, suggesting that the ...